We cover all therapeutic areas and multiple dosage forms but have a particular experience in small, well established molecules, as well as in drug repurposing,
unlicensed to licensed (UL2L) medicines within the European Union and other markets.
We offer regulatory non-clinical and clinical writing services for well established molecules with a focus of Article 10(a) and 10(3) applications.